目的:探讨阿帕替尼用于二线及二线以上治疗失败的晚期胃癌患者的临床疗效分析及预后因素研究.方法:研究对象为2014-10/2015-08曾接受过二线及二线以上治疗失败的60例晚期胃癌患者,均经病理确诊.给予阿帕替尼口服850m g/d,直至疾病进展,...目的:探讨阿帕替尼用于二线及二线以上治疗失败的晚期胃癌患者的临床疗效分析及预后因素研究.方法:研究对象为2014-10/2015-08曾接受过二线及二线以上治疗失败的60例晚期胃癌患者,均经病理确诊.给予阿帕替尼口服850m g/d,直至疾病进展,观察临床疗效及不良反应发生情况.应用Kaplan-Meier法进行生存分析.结果:根据实体瘤的疗效评定标准(Response Evaluation Criteria in Solid Tumors,RECIST)全部可评价疗效.其中完全缓解(complete response,CR)占0%(0/60),部分缓解(partial response,PR)占3.33%(2/60),疾病稳定(stable disease,SD)占38.33%(23/60),疾病进展(progressive disease,PD)占58.33%(35/60).客观缓解率(CR+PR)为3.33%,疾病控制率(CR+PR+SD)为38.33%(23/60).中位无进展生存期为3.76 mo.甲胎蛋白(a-f e t o p r o t e i n,A F P)阳性胃癌患者的疾病控制以及生存受益优于AFP阴性患者.高血压、骨髓抑制是影响阿帕替尼治疗的最主要的不良反应.结论:阿帕替尼治疗二线及二线以上治疗失败的晚期胃癌仍有较好的疾病控制及生存获益,不良反应可控制,值得临床上广泛应用.展开更多
Objective：The programmed cell death-1 receptor/programmed cell death-1 ligand （PD-1/PD-L1） pathway plays a crucial role in tumor evasion from host immunity.This study was designed to evaluate the association betwee...Objective：The programmed cell death-1 receptor/programmed cell death-1 ligand （PD-1/PD-L1） pathway plays a crucial role in tumor evasion from host immunity.This study was designed to evaluate the association between circulating PD-L1 expression and prognosis in patients with advanced gastric cancer.Methods：Totally 80 advanced gastric cancer patients and 40 health controls from Beijing Cancer Hospital were enrolled in the present study.Circulating PD-L1 expression was tested by enzymelinked immunosorbent assay （ELISA）.The associations between the expression level of PD-L1 and clinicopathological features and prognosis were analyzed statistically.Results：Expression of PD-L1 in advanced gastric cancer patients was significandy up-regulated compared with health people （P=0.006）.The expression of PD-L1 was significantly correlated with differentiation and lymph node metastasis （P=0.026 and P=0.041,respectively）.Although we didn＇t find significant difference in all advanced gastric cancer patients with different PD-L1 expression,the adenocarcinoma patients with higher up-regulated PD-L1 expression had much better prognosis than low expression patients （65.6％ vs.44.7％,P=0.028）.Conclusions：PD-L1 was elevated in advance gastric cancer patients and may play an important role in tumor immune evasion and patients prognosis.展开更多
文摘目的:探讨阿帕替尼用于二线及二线以上治疗失败的晚期胃癌患者的临床疗效分析及预后因素研究.方法:研究对象为2014-10/2015-08曾接受过二线及二线以上治疗失败的60例晚期胃癌患者,均经病理确诊.给予阿帕替尼口服850m g/d,直至疾病进展,观察临床疗效及不良反应发生情况.应用Kaplan-Meier法进行生存分析.结果:根据实体瘤的疗效评定标准(Response Evaluation Criteria in Solid Tumors,RECIST)全部可评价疗效.其中完全缓解(complete response,CR)占0%(0/60),部分缓解(partial response,PR)占3.33%(2/60),疾病稳定(stable disease,SD)占38.33%(23/60),疾病进展(progressive disease,PD)占58.33%(35/60).客观缓解率(CR+PR)为3.33%,疾病控制率(CR+PR+SD)为38.33%(23/60).中位无进展生存期为3.76 mo.甲胎蛋白(a-f e t o p r o t e i n,A F P)阳性胃癌患者的疾病控制以及生存受益优于AFP阴性患者.高血压、骨髓抑制是影响阿帕替尼治疗的最主要的不良反应.结论:阿帕替尼治疗二线及二线以上治疗失败的晚期胃癌仍有较好的疾病控制及生存获益,不良反应可控制,值得临床上广泛应用.
文摘Objective：The programmed cell death-1 receptor/programmed cell death-1 ligand （PD-1/PD-L1） pathway plays a crucial role in tumor evasion from host immunity.This study was designed to evaluate the association between circulating PD-L1 expression and prognosis in patients with advanced gastric cancer.Methods：Totally 80 advanced gastric cancer patients and 40 health controls from Beijing Cancer Hospital were enrolled in the present study.Circulating PD-L1 expression was tested by enzymelinked immunosorbent assay （ELISA）.The associations between the expression level of PD-L1 and clinicopathological features and prognosis were analyzed statistically.Results：Expression of PD-L1 in advanced gastric cancer patients was significandy up-regulated compared with health people （P=0.006）.The expression of PD-L1 was significantly correlated with differentiation and lymph node metastasis （P=0.026 and P=0.041,respectively）.Although we didn＇t find significant difference in all advanced gastric cancer patients with different PD-L1 expression,the adenocarcinoma patients with higher up-regulated PD-L1 expression had much better prognosis than low expression patients （65.6％ vs.44.7％,P=0.028）.Conclusions：PD-L1 was elevated in advance gastric cancer patients and may play an important role in tumor immune evasion and patients prognosis.
